Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Cash & Equivalents (2016 - 2025)

Traws Pharma's Cash & Equivalents history spans 14 years, with the latest figure at $3.8 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $3.8 million for Q4 2025, down 82.1% from a year ago — trailing twelve months through Dec 2025 was $3.8 million (down 82.1% YoY), and the annual figure for FY2025 was $3.8 million, down 82.1%.
  • Cash & Equivalents for Q4 2025 was $3.8 million at Traws Pharma, down from $6.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $59.4 million in Q3 2021 to a low of $3.8 million in Q4 2025.
  • The 5-year median for Cash & Equivalents is $27.5 million (2023), against an average of $29.7 million.
  • The sharpest move saw Cash & Equivalents surged 189.46% in 2021, then plummeted 82.1% in 2025.
  • Year by year, Cash & Equivalents stood at $55.1 million in 2021, then dropped by 29.62% to $38.8 million in 2022, then plummeted by 46.28% to $20.8 million in 2023, then increased by 2.48% to $21.3 million in 2024, then plummeted by 82.1% to $3.8 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $3.8 million, $6.4 million, and $13.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.